

## Tirzepatide TFA

Cat. No.:	HY-P1731A
Molecular Formula:	C <sub>227</sub> H <sub>349</sub> F <sub>3</sub> N <sub>48</sub> O <sub>70</sub>
Molecular Weight:	4927.47
Sequence Shortening:	Y-{Aib}-EGTFTSDYSI-{Aib}-LDKIAQ-{diacid-gamma-Glu-(AEEA)2-Lys}-AFVQWLIAGGPSS GAPPPS-NH <sub>2</sub>
Target:	GCGR
Pathway:	GPCR/G Protein
Storage:	Sealed storage, away from moisture Powder    -80°C    2 years -20°C    1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

### BIOLOGICAL ACTIVITY

Description	Tirzepatide TFA (LY3298176 TFA) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes <sup>[1]</sup> .
IC <sub>50</sub> & Target	Glucose-dependent insulinotropic polypeptide (GIP), GLP-1 receptor <sup>[1]</sup>

### REFERENCES

[1]. Frias JP, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-2193.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA